miR-34a overexpression resulted in increased sensitivity to paclitaxel while miR-34a down-regulation resulted in chemoresistance to paclitaxel in vitro. The overexpression of miR-34a increased the sensitivity of prostate cancer-3PR cells to chemotherapy in vivo. Western blot analysis and qRT-PCR confirmed that miR-34a inhibited the Notch1 signaling pathway. [Cell Physiol Biochem]
Full Article

The authors describe the contribution of prostate luminal progenitor cells to luminal cell development and their role in prostate development, androgen-mediated regeneration of castrated prostate, and tumorigenesis. [Trends Cancer]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

Trovagene, Inc. announced that it has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT). Under the agreement, Trovagene has exclusive rights to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase inhibitor for the treatment of cancer. [Trovagene, Inc.]
Press Release

Clovis Oncology, Inc. announced that the FDA has granted Breakthrough Therapy designation for Rubraca® as a monotherapy treatment of adult patients with BRCA1/2-mutated MCRPC who have received at least one prior androgen receptor-directed therapy and taxane-based chemotherapy. [Clovis Oncology, Inc.]
Press Release

Oncology Venture A/S announced that the Danish Medicines Agency has approved an application to broaden the scope of an ongoing Phase II study of LiPlaCis®. The authority clearance will allow inclusion of prostate cancer patients into the clinical study, which has so far been focused on evaluating the safety and efficacy of LiPlaCis® in breast cancer patients. [Oncology Venture A/S]
Press Release

Universities often tout their commitment to public outreach. But a new study of the internal guidelines for faculty tenure and promotion suggests that institutions don’t always put much value on public engagement. [Nature News]
Editorial

A month after European funders launched the ‘Plan S’ initiative to demand immediate open access to scientific literature in the next two years, the plan’s creators have revealed more details about their bold scheme — and are hurriedly trying to get support from US policymakers. [Nature News]
Editorial

A populist surge from a right-wing presidential candidate in Brazil that is threatening to upend the country’s politics could have huge impacts on research budgets and environmental policies. [Nature News]
Editorial